|Title||Director, Professor, doctoral advisor, chief physician and Doctor of Medicine|
He is also a member of the Neurosurgery Branch of Guangdong Medical Association, a member of Neurosurgeons Association of Guangdong Medical Doctor Association, a standing member of the Neurosurgery Branch of Guangdong Association of the Integrative Traditional and Western Medicine, Vice Chairman of Guangdong Anti-cancer Association and Society of Neuro-oncology, Guangzhou Anti-cancer Association, a member of the Branch of Minimally Invasive Therapy for Intracranial Tumors, Committee of Minimally Invasive Therapy, Chinese Anti-cancer Association, and Editorial Board Member of Chinese Journal of Neuro-oncology.Diagnosis and microsurgery treatment of nervous system (brain and spinal cord) tumors; combination therapy (surgery, chemotherapy, targeted therapy and immunotherapy) of brain glioma, and diagnosis and treatment of brain metastasis.
He has also conducted some research on nasopharynx carcinoma radiation encephalopathy, etc. and has carried out intracranial lesions stereotactic biopsy.
Prof. Mou Yonggao is Master and Doctor of Clinical Medicine of Sun Yat-sen University. He has been engaged in clinical work, scientific research and teaching on neurosurgery for over 20 years, and has been committed to clinical work and research work in neuro-oncology. He studied at MD Anderson Cancer Center in 2009.He has led a number of scientific research projects funded by National Natural Science Foundation of China, etc. and published several papers on SCI journals. He was granted a patten for utility model of the People's Republic of China.
|Title||Deputy Director and Associate Professor|
Ke Sai, M.D., Ph. D. is Associated Professor in the Department of Neurosurgery/Neuro-oncology at Sun Yat-sen University Cancer Center, Guangzhou, China. Dr. Sai received his medical degree from Sun Yat-sen University School of Medicine. He completed a residency and fellowship in neurosurgical oncology at Sun Yat-sen University Cancer Center, Guangzhou. Dr. Sai trained as a post-doctor supervised by Professor Alfred Yung and Professor Howard Colman from 2007 – 2009 at MD Anderson Cancer Center, Houston, where he was a recipient of MD Anderson Cancer Center Trainee Excellence Award (2009). Dr. Sai’s clinical interests are in the use of multimodality intraoperative monitoring techniques for the resection of brain tumors. He is also a NSFC-funded translational researcher who has published extensively on targeted therapies for glioma stem cells. He is a board member of the Chinese Society of Neuro-oncology (CSNO) and serves as an executive editor of the Glioma, which is the official journal of CSNO. Dr. Sai has published more than 30 peer-reviewed articles and book chapters.
Multimodality intraoperative monitoring techniques for the resection of brain tumors, and translational research on targeted therapy against malignant gliomas.
2009 Ph.D. Sun Yat-sen University, Medical School, P.R.China. Clinical Oncology
2004 M.S. Sun Yat-sen University, Medical School, P.R.China. Clinical Medicine
2002 M.D. Sun Yat-sen University, Medical School, P.R.China. Clinical Medicine
5/2007-4/2009 Postdoctoral fellowship, Department of Neuro-Oncology, UT MD Anderson Cancer Center, TX, U.S.A.
8/2004 The Australia and Asia Pacific Clinical Oncology Research Development Workshop. Sponsord by MOGA, AACR and ASCO
7/2004-12/2006 Clinical Residency, Sun Yat-sen University Cancer Center, Guangzhou, P.R.China
1. Hu WM, Wang F, Xi SY, Zhang X, Lai JP, Wu HY, Liu LL, Sai K#, Zeng J#. Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center. J Cancer. 2020.
|Title||Professor and Founder Chairman of the Department of Neurosurgery/Neuro-oncology|
Dr. Chen is a Professor and Founder Chairman in the Department of Neurosurgery/Neuro-oncology of Sun Yat-sen University Cancer Center. Dr. Chen is Founder president of Chinese Society of Neuro-Oncology(CSNO). Dr. Chen’s clinical interests include microsurgery and multimodality treatment for primary and metastatic tumors in central nervous system, particularly gliomas. Chemotherapy and immunotherapy are important adjuvant treatments in his clinical practice.
Dr. Chen’s research interests including: Genetic alterations leading to resistance of human brain tumors to chemotherapy, and has found that ERCC2, one of the important components in nucleotide excision repair (NER) system related to alkylating agent resistance in human tumor cell lines. MGMT associated drug resistance in glioma has also been investigated and applied in his clinical practice. He also, for the first time, has found that vasculogenic mimicry (VM), a new circulation exists in malignant gliomas. And, immunotherapy for glioma, such as CIK cell local therapy and DC-glioma fusion cells (FC), is also his investigating field. Last 20 years, Dr. Chen has also participated more than 20 clinical trials for glioma treatment as PI, Co-PI or investigator.For information on Professor Chen's laboratory, click here and select: Brain cancer genetic resistance/drug resistance in glioma/vasculogenic mimicry (VM) in glioma
MD (1982) Suzhou Medical College, Suzhou, China.
Ph.D. (1993) Suzhou Medical College, China
1982 –1987 Residency training for Neurosurgery, Suzhou Medical College, China.
1993-1999 Postdoctoral research fellow/research Associate, Neurosurgery/Oncology, McGill University, Montreal, Canada.
1. Shaoyan Xi, haiping cai, Jiabin Lu, Yu Zhang, yanjiao Yu, Furong Chen, Qitao Huang, and Fang Wang, Zhongping Chen. The pseudogene PRELID1P6 promotes glioma progression via the hnHNPH1-Akt/mTOR axis. Oncogene, published on line:09 June 2021.
2. Xin Mei, Yin-Sheng Chen, Qing-Ping Zhang, Fu-Rong Chen, Shao-Yan Xi, Ya-Kang Long, Ji Zhang, Hai-Ping Cai, Chao Ke, Jing Wang, Zhong-Ping Chen. Association between glioblastoma cell-derived vessels and poor prognosis of the patients. Cancer Communications. 2020;40:211–221.
3. Xiang-Rong Ni, Yi-Ying Zhao, Hai-Ping Cai, Zhi-Hui Yu, Jing Wang, Fu-Rong Chen, Yan-Jiao Yu, Guo-Kai Feng, Zhong-Ping Chen. Transferrin Receptor 1 Targeted Optical Imaging for Identifying Glioma Margin in Mouse Models. J Neurooncol. 2020，148：245–258.
4. Haiping Cai， Yanjiao Yu，Xiangrong Ni, Cong Li，Yuanjun Hu, Jing Wang, Furong Chen, Shaoyan Xi and Zhongping Chen. LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis. Cell Death and Disease (2020) 11:1032.
5. Hai-ping Cai, Jing Wang, Shao-yan Xi, Xiang-rong Ni, Yin-sheng Chen, Yan-jiao Yu, Zi-wen Cen, Zhi-hui Yu, Fu-rong Chen, Cheng-cheng Guo, Ji Zhang, Chao Ke, Jian Wang and Zhong-ping Chen. Tenascin-cmediated vasculogenic mimicry formation via regulation of MMP2/MMP9 in glioma. Cell Death Dis. 2019 Dec; 10(12): 879.IF5.959
6. Mei X, Chen YS, Chen FR, Xi SY, Chen ZP. Glioblastoma stem cell differentiation into endothelial cells evidenced through live cell imaging Running title: Live cell imaging of GSCs CD34 expression. Neuro Oncol. 2017 Mar 8. doi: 10.1093/neuonc/nox016. [Epub ahead of print], Neuro Oncol. 2017 Aug 1;19(8):1109-1118
7. Fu J, Yang QY, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP.TGM2 inhibition attenuates ID1 expression in CD44-high glioma-initiating cells. Neuro-oncology, 2013,15（10）：1353-1365
8. Liu XM,Zhang QP,Mu YG,Zhang XH,Sai K,Pang JC,Ng HK,Chen ZP.Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol,2011,(105 ):173-179.
9. Fu J,Shao CJ,Chen FR,NG HK,Chen ZP.Autophagy Induced by Valproic Acid is Associated with Oxidative Stress in Glioma Cell Lines.Neuro-oncology,2010,12(4):328-340.
10. Chen HY,Shao CJ,Chen FR,Kwan AL,Chen ZP.Role of ERCC1 Promoter Hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer,2010,126(8):1255-1259.
11. Yue WY,Yu SH, Zhao SG,Chen ZP. Molecular markers relating to malignant progression in grade II astrocytoma. J Neurosurgery,2009,110(4):709-14.
12. Shao CJ,Fu J,Shi HL,Mu YG,Chen ZP.Activities of DNA-PK and Ku86, but not Ku70, may predictsensitivity to cisplatin in human gliomas.J Neurooncol,2008,89(1):27-35.
13. Chen HY,Shao CJ,Shi HL,Mu YG,Sai K,Chen ZP.Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-à-vis chemotherapy drug cytotoxicity in human gliomas.J Neuro-oncology,2007,82:257-262.
14. Yue WY,Chen ZP.Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem.2005, 53(8):997-1002.
15. Chen ZP,Pan J,Huang Q,Sun ZF,Zhou LY,Wang AD.Antitumor efficacy of SarCNU in a Human Glioma Xenograft Model expressing both MGMT and Extraneuronal Monoamine Transporter.J Neuro-Oncology,2001,51:19-24.
16. Chen ZP,Carter CA,Alley MC,Mohr G,Panasci LC.Both Extraneuronal Monoamine Transporter and O6-methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of SarCNU in Human Tumor Xenografts.J Pharmacol Exp Ther,2001,296(3):712-715.
17. Wang ZM,Chen ZP,Xu ZY,Christodoulopoulos G,Bello V,Mohr G,Aloyz R,Panasci LC.In vitro evidence for homologous recombinational repair in resistance to melphalan.J Natl Cancer Inst,2001,93(19):1473-1478.
18. Chen ZP,Wang G,Huang Q,Sun ZF,Zhou LY,Wang AD,Panasci LC.Enhanced antitumor activity of SarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J Neuro-Oncology,1999,44:7-14.
19. Chen ZP,Remack J,Brent TP,Mohr G,Panasci LC.Extraneuronal Monoamine Transporter Expression vis-à-vis SauCNU Cytotoxicity in Human Tumor Cell Lines.Clinical Cancer Research, 1999,5:4186-4190.
20. Chen ZP,McQuillan A,Mohr G,Panasci LC.Excision repair cross-complementing rodent repair dificiency gene2 expression and chloroethylnitrosourea resistance in human glioma cell lines. Neurosurgery,1998,42(5)1112-1119.
21. Chen ZP,Malapetsa A,McQuillan A,Marcantonia D,Bello V,Mohr G,Remack J,Brent TP,Panasci LC.Evidence for nucleotide excision repair as a modifying factor of MGMT mediated innate chloroethylnitrosourea resistance in human tumor cell lines. Molecular Pharmacology,1997,52: 815-820.
22. Chen ZP,Malapetsa A,Marcantonio D,Mohr G,Brien S,Panasci LC.Correlation of chloroethylnitrosourea resistance with ERCC-2 expression in human tumor cell lines as determined by quantitative competitive polymerase chain reaction. Cancer Research ,1996,56: 2475-2478.
23. Chen ZP,Malapetsa A,Brien S,Mohr G,Panasci LC.Quantitation of ERCC-2 expression by reverse-transcription polymerase chain reaction comparison to Northern blot analysis. Anal Biochem,1997,244: 50-54.
Updated November 2021
|Title||Associate chief physician|
Prof. Wang Jian graduated from Guangzhou Medical University in 1993 and after that worked in the Department of Neurosurgery at the Second Affiliated Hospital of Guangzhou Medical University. He has accumulated rich clinical experience in the diagnosis and treatment of diseases such as nervous system tumors, brain trauma and cerebrovascular disease. He was a student of Liu Yunsheng, a famous Chinese expert in neurosurgery and Professor of Xiangya School of Medicine, Central South University, and was awarded a master's degree and a doctoral degree in neurosurgery in 1997 and 2003 respectively. He had been engaged in postdoctoral research in the Department of Neurosurgery at the University of Florida and conducted sphenoid sinus and temporal bone microdissection studies at Rhoton microdissection laboratory from August 2007 to September 2009.
Currently he serves as the Associate Chief Physician of the Department of Neurosurgery at Sun Yat-sen University Cancer Center and is engaged in clinical work and scientific research. He has carried out in-depth studies on the diagnosis and microsurgery treatment of skull base tumor and pediatric neural tumor. He is also a youth member of the Chinese Society of Neuro-oncology, Chinese Anti-cancer Association, a member of the Society of Pediatric Oncology, Guangdong Anti-cancer Association, and Editorial Board Member of the Chinese Journal of Neuro-oncology.
He has published over 20 papers on professional journals in and outside China and participated in the compilation and translation of three books on neurosurgery, namely Practical Microsurgery of Skull Base, Endoscopic Skull Base and Brain Surgery: Tips and Pearls, and Rhoton Cranial Microanatomy and Surgical Approaches. He was awarded the First Class of Scientific and Technological Progress Award at provincial level.
|Title||Associate chief physician and specialist in neuro-oncology chemotherapy|
Prof. Yang is a specialist in neurosurgery and neuro-oncology chemotherapy as well as a member in the glioma single disease expert group at Sun Yat-sen University Cancer Center. In 2012, she studied clinical neuro-oncology at the University of Texas MD Anderson Cancer Center which ranks first in tumor combination therapy in America. In 2013, she served as a visiting scholar at the Neurosurgery and Brain Tumor Center of Prince of Wales Hospital, the Chinese University of Hong Kong and was engaged in the clinical work on neuro-oncology. She has been engaged in clinical chemotherapy and combination therapy of various malignant tumors for over ten years. Through diagnosis and treatment on quite a number of brain metastasis and primary brain tumor patients, she has carried out a series of studies and exploration on nervous system tumors. She is one of the first batch of specialists in neuro-oncology chemotherapy in China. She has rich experience in chemotherapy of primary central nervous system tumor, brain metastasis and children and teenager malignant tumors. She is skilled in chemotherapy and individualized combination therapy for brain glioma, brain germ cell tumor, medulloblastoma, primitive neuroectodermal tumor, neuroblastoma, primary central nervous system lymphoma, malignant meningioma, ependymoma and brain metastasis, etc. She has been in charge of holding six "National Neuro-oncology Chemotherapy and Molecularly Targeted Drug Therapy Study Group" (national level continuing medical education program) since 2007.
She has participated in a number of multi-centric clinical trials of anti-tumor new drug (cytotoxic drug and molecularly targeted therapy drug) in and outside China. She has received a number of scientific research funds from National Natural Science Foundation of China, project of Development Center for Medical Science and Technology, Ministry of Health, P.R.China, project of Guangdong Provincial Department of Science and Technology, scientific research project of Health Department of Guangdong Province, project funded by Guangdong Provincial Association for Science and Technology (fund for young and middle-aged scientists and technicians to go abroad to participate in international academic conferences), and fund for scientific research on single diseases of Sun Yat-sen University Cancer Center. She is the Chief Editor of Handbook of Nervous System Tumor Chemotherapy. She also participated in the compilation of books such as Nervous System Tumors, and Clinical Practice Guidelines for Central Nervous System Tumors. And she has published over 30 papers in SCI journals and Chinese core journals.
Chemotherapy, molecularly targeted therapy and combination therapy for nervous system tumors.
1. Fu J, Yang QY（共同第一作者）, Sai K, Chen FR, Pang JC, Ng HK, Kwan AL, Chen ZP. TGM2 inhibition attenuates ID1 expression in CD44-high glioma -initiating cells.Neuro Oncol, 2013,15（10）：1353-1365. （SCI-IF:6.18分)
2. KE SAI,QUN-YING YANG,DONG SHEN,ZHONG-PING CHEN.Chemotherapy for gliomas in mainland China:An overview.ONCOLOGY LETTERS,2013,5:1448-1452.
3. Jiang XB,Yang QY,Sai K,Zhang XH,Chen ZP,Mou YG.Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center.Tumour Biol,2011,32(6):1249-1256.
4. Chen LK,Liang Y,Yang QY, Xu F,Zhou NN,Xu GC,Liu GZ,Wei WD.Triplet platinum -based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev,2012;13(5):1863-1867.
5. Zhang GH,Jiang XB,Zhang XH,Sai K,Yang QY,Chen ZP,Mou YG.Correlation between TGF-β1 expression and Treg cell infiltration in glioma.Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi,2011,27(6):680-682.
6. Mou YG, Sai K, Wang ZN, Zhang XH, Lu YC, Wei DN, Yang QY, Chen ZP. Surgical management of radiation-induced temporal lobe necrosis in patients with nasopharyngeal carcinoma: Report of 14 cases.Head Neck,2011,33(10):1493-500.
7. Zhen-ye Li, Xiang-heng zhang，Yu Chen，Jian-gui Guo，Ke Sai，Qun-ying Yang， Zhong-ping Chen，Yong-gao Mou, .Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. OncoTargets and Therapy, 2013:6 869–875.( SCI-IF:2.073)
Dr Xiao-Bing Jiang is currently an Associate Professor in the Department of Neurosurgical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. He graduated from Sun Yat-sen University with a doctor degree. He was admitted to Harvard Medical School and Massachusetts General Hospital twice as a visiting scholar. He is a member of the CHINA PITUITARY ADENOMAS SPECIALIST COUNCIL, CHINA ANTI-CANCER ASSOCIATION, GUANGDONG MEDICAL ASSOCIATION, GUANGDONG MEDICALN DOCTOR ASSOCIATION, the secretariat and the youth member of Guangdong Provincial Anticancer Association. In recent years, he published 18 papers in international professional journals including Molecular Cancer, J Clin Endocrinol Metab, Endocrine Practice, J neuro-oncol and Pituitary as the first author or corresponding author. He has presided over a number of research projects including national Natural Science Foundation of China and provincial Natural Science Foundation of China.
He specializes in performing trans-nasal endoscopic surgery to resect sellar tumors, including pituitary adenoma, craniopharyngioma, chordoma and osteochondroma. Research focus in application of artificial intelligence in diagnosis and treatment of pituitary tumor, relationship between epigenetic regulation and incidence of pituitary tumor.
2001.09 - 2006.06 Southwest Medical University, Bachelor
2006.09 - 2009.06 Sun Yat-sen University, Master
2011.09 - 2014.06 Sun Yat-sen University, Ph.D
2013.02 - 2014.02 Neurosurgery/Neuroendocrinology Laboratory, Massachusetts General Hospital, Ph.D
1. Hongyu Li, Qi Zhao, Yihua Zhang, Ke Sai, Lunshan Xu, Yonggao Mou, Yubin Xie, Jian Ren, Xiaobing Jiang#. Image-driven classification of functioning and nonfunctioning pituitary adenoma by deep convolutional neural networks. Computational and Structural Biotechnology Journal. 19 (2021) 3077-3086.
2. Qiu Du, Bin Hu, Yajuan Feng, Zongming Wang, Xin Wang, Dimin Zhu, Yonghong Zhu, Xiaobing Jiang#, Haijun Wang#. CircOMA1 mediated miR-145-5p suppresses tumor growth of nonfunctioning pituitary adenomas by targeting TPT1. J Clin Endocrinol Metab. 2019 Jun 1;104(6):2419-2434.
3. Liping Tan*, Dongmei Mai*, Bailin Zhang*, Xiaobing Jiang*, Jialiang Zhang,1, et al. PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. Mol Cancer. 2019 Jan 12;18(1):9. doi: 10.1186/s12943-019-0940-3.
4. Hao Duan, Zhen-Qiang He, Cheng-Cheng Guo, Jue-Hui Li, Jian Wang, Zhe Zhu, Ke Sai, Zhong-Ping Chen, Xiao-Bing Jiang#, Yong-Gao Mou#. Bone metastasis predicts poor prognosis of patients with brain metastases from colorectal carcinoma post aggressive treatment, Cancer Management and Research, 2018.08, 10:2467-2474.
5. Xiao-bing Jiang, Yin-sheng Chen, Zhi-huan Zhou, Li-Ping Luo, Wang-ming Hu, Zhong-Ping Chen, Jian Wang. Surgical Resection of Pineal Epidermoid Cyst Contributed to Relieving Schizophrenia Symptoms. World Neurosurgery, 2018.05, 113:304-307.
6. Xiao-Bing Jiang, Jing Zhang, Cui-ling Li, Zhi-Gang Mao,Bin Hu, Zhe Zhu,Yong-Hong Zhu,Hai-Jun Wang. Subclinical impairment of the left ventricular longitudinal function in patients with prolactinomas. ENDOCRINE PRACTICE. Vol 23 No. 12 December 2017 1379-1386.
7. Shi-Yuan Yu, Qiu Du, Si-Yuan Yao, Ke-Nan Zhang, Jian Wang, Zhe Zhu, Xiao-bing Jiang. Outcomes of endoscopic and microscopic transsphenoidal surgery on nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Journal of Cellular and Molecular Medicine,2018 03;22(3):2023-2027.
8. Zhen-qiang He, Hao Duan, Chao Ke, Xiang-heng Zhang, Cheng-cheng Guo, Fuad Al-Nahari, Ji Zhang, Zheng-he Chen, Yin-sheng Chen, Zhi-gang Liu, Jian Wang, Zhong-ping Chen, Xiao-Bing Jiang#, Yong-Gao Mou#. Evaluation of cumulative prognostic score based on pretreatment plasma fibrinogen and serum albumin levels in patients with newly diagnosed high-grade. Oncotarget. 2017 Jul 25;8(30):49605-49614. doi: 10.18632/oncotarget.17849.
9. He ZQ, Ke C, Al-Nahari F, Duan H, Guo CC, Wang Y, Zhang XH, Chen YS, Liu ZG, Wang J, Chen ZP, Jiang XB#, Mou YG#. Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade glioma. J Neurooncol. 2017, 132(2):239-247.
10. Jiang XB, Hu B, He DS, Mao ZG, Wang X, Song BB, Zhu YH, Wang HJ. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases. BMC Cancer, 2015, 15: 644-644
11. Jiang XB, Li CL, He DS, Mao ZG, Liu DH, Fan X, Hu B, Zhu YH, Wang HJ. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary. 2014, 17(3):232-239.
12. Jiang XB, Zhang X, The molecular pathogenesis of pituitary adenomas: an update. Endocrinol Metab (Seoul),2013,28(4):245-254.
13. Jiang XB, He DS, Mao ZG, Fan X, Lei N, Hu B, Song BB, Zhu YH, Wang HJ. BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort. Tumour Biology, 2013, 34(2):1171-1176.
14. Jiang XB, Yang QY, Sai K, Zhang XH, Chen ZP, Mou YG. Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center. Tumour Biology, 2011,32(6):1249-1256.
15. Jiang XB, Ke C, Zhang GH, Zhang XH, Sai K, Chen ZP, Mou YG. Brain metastases from hepatocellular carcinoma: Clinical features and prognostic factors. BMC Cancer, 2012 Feb. 1;12:49.
16. Jiang XB, Yuan WS, Wang JS, Liu Z, Liu DH, Shi ZS. Matrix metalloproteinase-9 expression in carotid atherosclerotic plaque and contrast-enhanced MRI in a swine model. J Neurointerv Surg, 2014,6(1):24-28.
17. Jiang XB, Wang JS, Liu DH, Yuan WS, Shi ZS. Overexpression of matrix metalloproteinase-9 is correlated with carotid intraplaque hemorrhage in a swine model. J Neurointerv Surg, 2013,5(5):473-477.
18. Jiang XB, Ke C, Han ZA, Lin SH, Mou YG, Luo RZ, Wu SX, Chen ZP. Intraparenchymal papillary meningioma of brainstem: Case report and literature review. World J Surg Onco, 2012 Jan 12;10:10.
Updated November 2021